Trial Review

Reset your password and enable multi-factor authentication (MFA)


For ANZCTR account holders: to help ensure the cyber safety of your account, you’ll need to reset your password and set-up multi-factor authentication (MFA) as per the instructions below.


  1. Go to the Login page, click ‘reset password’ and follow the instructions.
  2. Check your email for the link to set a new password.
  3. Create a new password that meets requirements.
  4. Return to the Login page and enter your new password. A verification code will be sent to your email.
  5. Check your email for the code and enter it on the Login page. If the code is entered incorrectly, you can re-enter the correct one or request a new one.

Learn more about MFA and its importance on the Australian Signals Directorate website.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12624000473561
Ethics application status
Approved
Date submitted
2/04/2024
Date registered
16/04/2024
Date last updated
22/06/2025
Date data sharing statement initially provided
16/04/2024
Type of registration
Prospectively registered

Titles & IDs
Public title
A Phase I, Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of OXT-328 in Patients with Chemotherapy-Induced Peripheral Neuropathy. (Part C)
Scientific title
A Phase I, Randomised, Double Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of OXT-328 in Patients with Chemotherapy-Induced Peripheral Neuropathy. (Part C)
Secondary ID [1] 311691 0
OXT328-NEU-01
Universal Trial Number (UTN)
Trial acronym
Linked study record
This record is a sub study of ACTRN12624000374561

Health condition
Health condition(s) or problem(s) studied:
Chemotherapy-Induced Peripheral Neuropathy (CIPN) 333153 0
Condition category
Condition code
Neurological 329851 329851 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
This is a Phase Ia/b, randomised double blind, placebo-controlled, multiple dose, multi-cohort study.

Part C: (Multiple Doses) in patients with chemotherapy-induced peripheral neuropathy (CIPN).
Part C may commence following completion of SRC review of Part B (ACTRN12624000374561).

Twenty five patients with CIPN will be enrolled to 1 of 2 treatment area groups according to the extremity where patients experience CIPN: Hand (Group 1) or Foot (Group 2). Following enrolment to either Group 1 or 2, patients will be randomised to receive doses of OXT-328 or placebo administered as a topical gel.

Group 1: For patients administered treatment on hand: Dose level of 50 mg (1 mL of 5.0% w/w strength study drug) is planned to be evaluated.
Group 2: For patients administered treatment on foot: Dose level of 100 mg (2 mL of 5.0% w/w strength study drug) is planned to be evaluated

Doses will be administered on Days 1 to 28 (inclusive), with the dosing schedule three times daily. Site staff will administer the first dose on Day 1 and subsequently supply all patients with study drug (OXT-328 or placebo). Patients will be instructed to administer the first dose on Days 2, 7, 14 and 28 in the clinic (under the supervision of site staff) following completion of study assessments, with all other doses will be self-administered at home .

Adherence to Intervention will be managed via recording in appropriate drug accountability records.
Intervention code [1] 328154 0
Treatment: Drugs
Comparator / control treatment
The placebo gel contains no active ingredient and is formulated to match the consistency of OXT-328 gel. Placebo may be slightly different in colour to the OXT-328 drug product and may not exactly match the appearance of OXT-328 upon contact with skin. The placebo gel is also odourless and will also be supplied in an identical 50 gram tube as the OXT-328 gel. Composition of the gel includes quinoline yellow, ethanol, hypromellose, xanthan gum, glycerol, sodium citrate, citric acid, trolamine, benzalkonium and purified water.
Control group
Placebo

Outcomes
Primary outcome [1] 337619 0
To evaluate the safety and tolerability of OXT-328 following multiple doses of OXT-328 topical gel compared with placebo in patients with CIPN
Timepoint [1] 337619 0
Adverse events - will be graded using a five-point severity scale (mild, moderate, severe, life-threatening, death) and assessed continuously as they are reported or observed and reviewed daily from Screening until Day 35 (End of Study/Early Termination [EOS/ET]). Vital signs - Blood pressure and heart rate is measured using sphygmomanometer respiratory rate by manual breath count, temperature by thermometer. Measured from Screening, Day -1, pre-dose Day 1 0.25 hr, 4hrs post-dose, pre-dose Day 2 - 0.25 hr, 1 hr and 4 hrs post-dose, pre-dose Day 7 1 hr post-dose, pre-dose Day 14 1 hr post-dose, pre-dose Day 28 1 hr post-dose and Day 35 (EOS/ET). Clinical Laboratory Assessments (haematology, serum chemistry and urinalysis) blood and urine will be collected at Screening, Day -1, pre-dose Day 1, pre-dose Day 2, pre-dose Day 7, pre-dose Day 14, pre-dose Day 28 and Day 35 (EOS/ET). Full physical assessment will include at a minimum, assessment of the following: general appearance, head, ears, eyes, nose, and throat examination, neck (including thyroid and nodes), cardiovascular, respiratory, GI, renal, neurological, musculoskeletal, skin and occur at Screening and Day 35 (EOS/ET) with symptom directed assessments to occur at Day -1 and any time pre and post-dose Day 1, Day 2. Day 7, Day 14, and Day 28. Electrocardiogram (ECG) 12-lead ECG recordings will be obtained in triplicate at Screening, Day -1, pre-dose Day 1 1 hr post-dose, pre-dose Day 2 1 hr post-dose, pre-dose Day 7 1 hr post-dose, pre-dose Day 28 1 hr post-dose and ET visit. Local tolerability will be graded using a Local Skin Tolerability Questionnaire and assessed pre-dose Day 14 hrs post-dose, pre-dose Day 2 4 hrs post-dose, pre-dose Day 7, pre-dose Day 14 4 hrs post-dose, pre-dose Day 28 and Day 35 (EOS/ET). Assessment of use of rescue analgesics will be carried out upon review of patient diary at clinic visits on Day 2, Day 7, Day 14, Day 28 and and Day 35 (EOS/ET).
Secondary outcome [1] 433759 0
Exploratory Outcome: To determine the proportion of treatment responders in response to OXT-328 topical gel (Part C).
Timepoint [1] 433759 0
EORTC QLQ-CIPN20 assessment will be conducted pre-dose on Day 1 and at any time on Day 28.
Secondary outcome [2] 433756 0
Exploratory Outcome: To evaluate the relief of symptoms of CIPN during treatment with OXT-328 topical gel in patients with CIPN
Timepoint [2] 433756 0
EORTC QLQ-CIPN20 assessment will be conducted pre-dose on Day 1 and at any time on Day 28.
Secondary outcome [3] 432545 0
Exploratory Outcome: To evaluate the relief of symptoms of CIPN during treatment with OXT-328 topical gel in patients with CIPN
Timepoint [3] 432545 0
NRS assessment will be conducted at Screening, pre-dose on Day 1 - 1, 2, 6 hrs post-dose, pre-dose Day 2, pre-dose Day 7, pre-dose Day 14, pre-dose Day 28 and Day 35 End of Study/Early Termination Visit (EoS/ETV).
Secondary outcome [4] 432544 0
To evaluate the pharmacokinetics (PK) plasma profile of OXT-328 following multiple topical doses in patients with CIPN.
Timepoint [4] 432544 0
Blood plasma samples to be collected pre-dose Day 14 - 1, 2, 4 and 6 hrs post-dose,
Secondary outcome [5] 432547 0
Exploratory Outcome: To determine the proportion of treatment responders in response to OXT-328 topical gel (Part C).
Timepoint [5] 432547 0
NRS assessment will be conducted at Screening, pre-dose on Day 1 - 1, 2, 6 hrs post-dose, pre-dose Day 2, pre-dose Day 7, pre-dose Day 14, pre-dose Day 28 and Day 35 End of Study/Early Termination Visit (EoS/ETV).

Eligibility
Key inclusion criteria
Participants will be included in Part C of the study only if they satisfy all the following criteria:
1. Must have given written informed consent, before any study-related activities are carried out and must be able to understand the full nature and purpose of the trial, including possible risks and adverse effects.
2. Male or female, aged greater than or equal to 18 years, inclusive at Screening.
3. Have moderate-to-severe CIPN as defined by a NRS score of greater than or equal to 4 and less than or equal to 9 on a 0 – 10 scale for the participant’s experience of all CIPN-related symptoms.
4. Presence of CIPN for more than 3 months and less than 24 months at the time of Screening.
5. Participant is otherwise medically healthy (in the opinion of the Investigator [or delegate]), as determined by pre-study medical history and without clinically significant abnormalities including:
a. Physical examination without any additional clinically relevant findings
b. Heart rate in the range of 40 to 100 beats/minute after 5 minutes rest in supine or semi-supine position.
c. Body temperature (tympanic), between 35.5°C and 37.7°C.
d. Electrocardiogram without clinically significant abnormal findings.
e. No clinically significant findings in serum chemistry, haematology, or urinalysis.
6. Female participants must be of non-childbearing potential i.e., surgically sterilised (hysterectomy, bilateral salpingectomy, bilateral oophorectomy at least 6 weeks before the screening visit) or postmenopausal (where postmenopausal is defined as no menses for 12 months without an alternative medical cause and a FSH level consistent with postmenopausal status, per local laboratory guidelines), or, if of childbearing potential:
a. Must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test on Day -1, prior to dose administration.
b. Must agree not to donate ova or attempt to become pregnant from the time of signing consent until at least 30 days after the last dose of study drug.
c. If not exclusively in a same-sex relationship, must agree to use adequate contraception (which is defined as use of a condom by the male partner combined with use of a highly effective method of contraception from one month prior to screening until at least 30 days after the last dose of study drug.
7. Male participants must:
a. Agree not to donate sperm from the time of signing consent until 90 days after the last dose of study drug.
b. If engaging in sexual intercourse with a female partner who could become pregnant, agree to use adequate contraception (defined as use of a condom plus a highly effective method of contraception) from the time of signing consent until at least 90 days after the last dose of study drug.
c. If engaging in sexual intercourse with a female partner who is not of childbearing potential or a same-sex partner, agree to use a condom from the time of signing consent until at least 90 days after the last dose of study drug.
8. Negative urine drugs of abuse test at Screening or pre-dose on Day 1.
Note: Patients with positive drug screen for a known prescribed concomitant medication that is not otherwise exclusionary (e.g., benzodiazepines) may be permitted.
9. Willing and able to comply with all scheduled visits, treatment plans, laboratory tests and other study procedures.
10. Must be able to comprehend the language used in the quality of life and CIPN disease assessments in this clinical study, as assessed by the Investigator (or delegate).
Minimum age
18 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Participants will be excluded from Part C of the study if there is evidence of any of the following:
1. Experienced myocardial infarction or undergone coronary artery bypass grafting within 6 months of Screening.
2. Diagnosed with New York Heart Association (NYHA) Class III or IV heart failure.
3. History of hypersensitivity reaction, anaphylaxis or other clinically significant reactions or known allergy to any of the study drug ingredients (including any of its metabolic derivatives – sulindac, sulindac sulfone and sulindac sulfide), or any other NSAIDs.
4. Recent history (within 3 months of Screening) or currently existing gastric ulcers, non-iatrogenic intestinal perforation, or GI bleeding from NSAID usage for which intervention was required.
5. History of any clinically significant disorder (which, in the opinion of the Investigator [or delegate] would make implementation of the protocol or interpretation of study results difficult, or that would put the subject at risk by participating in the study), including cardiovascular, haematologic, pulmonary, hepatic, renal, gastrointestinal (GI), connective tissue, uncontrolled endocrine/metabolic (including but not limited to diabetes), neurologic, and psychiatric, alcohol abuse or addiction or any disorder that may prevent the successful completion of the study or influence the absorption, distribution, metabolism, excretion, or action of the study drug (including any of its metabolic derivatives – sulindac, sulindac sulfone and sulindac sulfide).
6. History of surgery within 8 weeks prior to Screening, or surgery planned during the study.
Note: history of, or planned dental surgery, eye surgery, and/or minor cosmetic procedures not in the hands or feet within the above timeframes are permitted.
7. Currently receiving chemotherapy for the treatment of neoplasia.
8. Experience neuropathic pain due to conditions other than CIPN, including postherpetic neuralgia, diabetes mellitus, human immunodeficiency virus (HIV) infection, spinal cord injury, tumor or metastasis affecting the cervical/lumbosacral plexus with evidence of tumor-associated pain, and other neurological diseases.
9. Presence of any tattoos, scarring or active skin infection or other condition (including open sores, pressure ulcers, stasis ulcers, or other dermatitides), which (in the opinion of the Investigator [or delegate]) would interfere with skin local tolerability assessments at the study drug application site.
10. Laboratory results at Screening that indicate inadequate renal function (estimated creatinine clearance of < 60 mL/min calculated by the Cockcroft and Gault formula).
11. Liver function test results elevated more than 2-fold above the upper limit of normal (ULN) for gamma glutamyl transferase (GGT), alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine transaminase (ALT) or total bilirubin. Participants with GGT, ALP and/or ALT/AST above the limits specified may be included, at the discretion of the Investigator, if the levels are unaccompanied by clinical signs and are determined to be normal variants.
12. Any clinically relevant laboratory finding or medical condition that, in the opinion of the Investigator, could place the patient at risk for participation in the study.
13. Use of topical, non traditional, or non-pharmacological therapy for the treatment of their pain (e.g., chiropractic therapies, alternative medicine therapies, or acupuncture) from 7 days prior to first dose of study drug to End of Study. These treatments are not to be used throughout the study.
Note: Use of paracetamol (less than or equal to 3 doses per week) is allowed for management of headaches or minor pains unrelated to CIPN.
14. Patient currently using antipsychotics, opiates/opioids, cannabinoids, hypnotics, antidepressants, mood stabilizers, stimulants or gabapentinoids. Patient may be permitted to participate in the study if they are using any of these medications on a chronic basis, with stable regimen for at least four weeks prior to Screening (and regimen to remain unchanged throughout the study). Up to 8 patients in total may be permitted to use EACH of the above group of medications throughout the study.
Note: For patients permitted to use the above medications throughout the study:
• Patient is not permitted to change medication throughout the study
• If using cannabinoids, must be supplied by medical dispensary and permitted by local laws to be used for medical reasons as instructed by the patient’s physician.
• If using opioids, dose must not exceed a morphine equivalent daily dose of 100mg.
15. Participation in another clinical study of an investigational drug or investigational device within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to Screening.
16. Participant is breastfeeding or pregnant, or planning to breastfeed or become pregnant during the study.
17. Known substance or alcohol abuse or medical, psychological, or social conditions that, in the opinion of the PI (or delegate), may interfere with the participants inclusion in the clinical study or evaluation of the clinical study results.
18. Any other condition or prior therapy that in the opinion of the Investigator (or delegate) would make the participant unsuitable for this study, including inability to cooperate fully with the requirements of the study protocol or likelihood of noncompliance with any study requirements.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All study participants will receive a unique sequential number and will be assigned a randomisation number prior to first dose administration, which corresponds to a study treatment (OXT-328 or placebo). The randomisation schedule will be prepared by an unblinded statistician and maintained under controlled access. A copy of the randomisation schedule will be provided to unblinded personnel responsible for dispensing the study drugs. The unblinded personnel will store the randomisation schedule in a secure, restricted access area. Code break envelopes will be provided to clinic site prior to first dose administration in the study.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
The allocation to OXT-328 or placebo will be performed using a block randomisation algorithm and will be documented in the study randomisation schedule.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

Intervention assignment
Parallel
Other design features
Phase
Phase 1
Type of endpoint/s
Safety
Statistical methods / analysis
This is a FIH study for OXT-328. As such, no formal sample size calculations have been performed, and the sample size is empirical.
The sample size of 20 patients with CIPN in Part C are considered adequate to meet the objectives of the study.

Recruitment
Recruitment status
Recruiting
Date of first participant enrolment
Anticipated
30/04/2024
Actual
26/11/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
25
Accrual to date
15
Final
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 26243 0
Scientia Clinical Research - Randwick
Recruitment postcode(s) [1] 42211 0
2031 - Randwick

Funding & Sponsors
Funding source category [1] 316019 0
Commercial sector/Industry
Name [1] 316019 0
Cleothena Enterprises Pty Ltd
Country [1] 316019 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Cleothena Enterprises Pty Ltd
Address
Country
Australia
Secondary sponsor category [1] 318171 0
Commercial sector/Industry
Name [1] 318171 0
Avance Clinical Pty Ltd
Address [1] 318171 0
Country [1] 318171 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 314843 0
Bellberry Human Research Ethics Committee J
Ethics committee address [1] 314843 0
Ethics committee country [1] 314843 0
Australia
Date submitted for ethics approval [1] 314843 0
20/12/2023
Approval date [1] 314843 0
23/02/2024
Ethics approval number [1] 314843 0
2023-12-1584

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 132898 0
Dr Christopher Argent
Address 132898 0
Scientia Clinical Research, Bright Building, Level 5, Corner High and Avoca Street, Randwick, NSW 2031
Country 132898 0
Australia
Phone 132898 0
+61 458 639 115
Fax 132898 0
Email 132898 0
[email protected]
Contact person for public queries
Name 132899 0
Christopher Argent
Address 132899 0
Scientia Clinical Research, Bright Building, Level 5, Corner High and Avoca Street, Randwick, NSW 2031
Country 132899 0
Australia
Phone 132899 0
+61 458 639 115
Fax 132899 0
Email 132899 0
[email protected]
Contact person for scientific queries
Name 132900 0
Christopher Argent
Address 132900 0
Scientia Clinical Research, Bright Building, Level 5, Corner High and Avoca Street, Randwick, NSW 2031
Country 132900 0
Australia
Phone 132900 0
+61 458 639 115
Fax 132900 0
Email 132900 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.